 |
市场调查报告书
商品编码
1738459
失智症药物市场按药物类别、适应症、给药途径、分销管道和地区划分Dementia Drugs Market, By Drug Class, By Indication, By Route of Administration, By Distribution Channel,By Geography |
||||||
2025 年失智症药物市场规模估计为 261.4 亿美元，预计到 2032 年将达到 414.5 亿美元，2025 年至 2032 年的复合年增长率为 6.8%。
| 报告范围 | 报告详细信息 | ||
|---|---|---|---|
| 基准年 | 2024 | 2025年的市场规模 | 261.4亿美元 |
| 效能数据 | 2020-2024 | 预测期 | 2025-2032 |
| 预测期：2025-2032年复合年增长率： | 6.80% | 2032年价值预测 | 414.5亿美元 |
在全球范围内，阿兹海默症和其他失智症患者人数的不断增加，推动了失智症药物市场的成长。失智症是由影响大脑的疾病（例如阿兹海默症和中风）引起的一种综合症。失智症的特征是逐渐丧失思考、记忆和推理等认知功能。随着人们对失智症诊断和治疗方法认识的不断提高，越来越多的人正在寻求医疗帮助来缓解失智症症状。一些製药公司正在大力投资研发有效药物，以减缓或阻止失智症的进展。
市场动态
失智症药物市场的成长主要得益于全球人口的快速老化，这增加了神经退化性疾病的风险。新兴市场医疗支出的增加以及生物製药公司加强研发力度，进一步促进了市场扩张。然而，高昂的药物开发成本构成了重大挑战，尤其是许多候选分子在后期临床试验中失败以及这些疾病的复杂性。最近核准的旨在影响缓解疾病药物对製造商来说是一个巨大的机会。政府对失智症研究的支持和资金不断增加，正在鼓励市场参与企业创新和开发新的治疗方法。由于人口结构变化导致失智症盛行率持续上升，对有效治疗方法的需求预计将增长，市场有望取得重大进展。
本研究的主要特点
本报告对全球失智症治疗药物市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和年复合成长率（CAGR%）。
它还强调了各个领域的潜在商机，并说明了该市场的引人注目的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
全球失智症药物市场主要企业的概况基于公司亮点、产品系列、主要成就和策略等参数。
主要企业包括 Biogen、Eisai Co., Ltd.、Novartis AG、Cipla、H. Lundbeck A/S、Otsuka Pharmaceutical Co., Ltd.、Sun Pharmaceutical Industries Ltd.、Viatris Inc.、Mapi-Pharma Ltd.、AbbVie, Inc.、DACHICHI 和 SANKYOs, LILINKYO, Ltd.AbbVie, Inc.、DACHIIImann SANKYOMPA CO, LILIMIA Ltd.、AbbVie, Inc.、DACHIC SANKNKYO CO, LILINK A.、AbbVie
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
全球失智症药物市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过用于分析全球失智症药物市场的各种策略矩阵来促进他们的决策。
目录
第一章 调查目的与前提条件
- 研究目标
- 先决条件
- 简称
第二章 市场展望
- 报告描述
- 市场定义和范围
- 执行摘要
第三章市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 主要亮点
- 监管情景
- 产品发布/核准
- PEST分析
- 波特分析
- 併购场景
- 流行病学
- 管道分析
第四章。失智症药物市场（按药物类别划分），2020-2032 年
- MAO抑制剂
- 胆碱酯酶抑制剂
- 麸胺酸抑制剂
- 其他的
第五章。失智症药物市场（按适应症划分），2020 年至 2032 年
- 阿兹海默症失智症
- 路易氏体失智症
- 帕金森氏症失智症
- 其他的
第六章失智症药物市场（依给药途径），2020 年至 2032 年
- 口服
- 静脉
- 其他的
第 7 章失智症药物市场（按分销管道划分），2020 年至 2032 年
- 医院药房
- 零售药局
- 网路药局
第 8 章失智症药物市场（按地区划分），2020 年至 2032 年
- 北美洲
- 美国
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 欧洲
- 德国
- 英国
- 西班牙
- 法国
- 义大利
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 澳洲
- 韩国
- ASEAN
- 其他亚太地区
- 中东
- 海湾合作委员会国家
- 以色列
- 其他中东地区
- 非洲
- 南非
- 北非
- 中部非洲
第九章 竞争态势
- Biogen
- Eisai Co., Ltd.
- Novartis AG
- Cipla
- Lundbeck A/S
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- Mapi-Pharma Ltd.
- AbbVie, Inc.
- DAIICHI SANKYO COMPANY, LIMITED.
- Hoffmann-La Roche Ltd
第十章 分析师建议
- 命运之轮
- 分析师观点
- Coherent Opportunity Map
第 11 章参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
The dementia drugs market size is estimated to be valued at US$ 26.14 Bn in 2025 and is expected to reach US$ 41.45 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.8% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 26.14 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 6.80% | 2032 Value Projection: | USD 41.45 Bn |
Dementia drugs market growth is driven by rising cases of Alzheimer's and other forms of dementia worldwide. Dementia is a syndrome caused due to disorders that affect the brain, such as Alzheimer's disease or strokes. It is characterized by a gradual loss of cognitive functions like thinking, remembering and reasoning. Increasing awareness about diagnosis and availability of treatment options drive more people to seek medical help for dementia symptoms. Several pharmaceutical companies are investing heavily in research and development of effective drugs to slow down or stop the progression of dementia.
Market Dynamics
Dementia drugs market growth is primarily driven by rapidly aging global population, which increases the risk of neurodegenerative conditions. Rising healthcare expenditures in developing nations and intensive R&D efforts by biopharmaceutical firms further contribute to market expansion. However, high drug development costs, particularly due to the failure of many candidate molecules in late-stage trials and the complexity of these diseases, pose significant challenges. The recent approval of disease-modifying drugs that aim to impact disease etiology rather than merely alleviating symptoms presents substantial opportunities for manufacturers. Increased government support and funding for dementia research are encouraging market participants to innovate and develop new therapies. As the prevalence of dementia continues to rise, driven by demographic changes, the demand for effective treatments is expected to grow, positioning the market for significant advancements.
Key features of the study
This report provides in-depth analysis of the global dementia drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dementia drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Biogen, Eisai Co., Ltd., Novartis AG, Cipla, H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Mapi-Pharma Ltd., AbbVie, Inc., DAIICHI SANKYO COMPANY, LIMITED., and F. Hoffmann-La Roche Ltd
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global dementia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dementia drugs market
Market Segmentation
- By Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- MAO Inhibitors
- Cholinesterase Inhibitors
- Glutamate Inhibitor
- Others
- By Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Alzheimer's Disease Dementia
- Lewy Body Dementia
- Parkinson Disease Dementia
- Others
- By Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Intravenous
- Others
- By Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Biogen
- Eisai Co., Ltd.
- Novartis AG
- Cipla
- Lundbeck A/S
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- Mapi-Pharma Ltd.
- AbbVie, Inc.
- DAIICHI SANKYO COMPANY, LIMITED.
- Hoffmann-La Roche Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Dementia Drugs Market, By Drug Class
- Dementia Drugs Market, By Indication
- Dementia Drugs Market, By Route of Administration
- Dementia Drugs Market, By Distribution Channel
- Dementia Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
- Pipeline Analysis
4. Dementia Drugs Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- MAO Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cholinesterase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Glutamate Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Dementia Drugs Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Alzheimer's Disease Dementia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lewy Body Dementia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parkinson Disease Dementia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Dementia Drugs Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Dementia Drugs Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Dementia Drugs Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mapi-Pharma Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- DAIICHI SANKYO COMPANY, LIMITED.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
失智症治疗市场规模、份额、趋势分析报告：按适应症、药物类别、给药途径、分销管道、地区、细分预测，2025-2030 年
2025-2033 年痴呆症药物市场（依适应症、药物类别、配销通路和地区划分）
失智症药物市场：依适应症、药物类别划分 - 2025-2030 年全球预测
痴呆症治疗市场，按适应症、按药物类别、按配销通路、按国家和地区划分 - 2024-2032 年行业分析、市场规模、市场份额和预测失智症治疗市场 - 按药物类别（胆碱酯酶、NMDA 受体、谷氨酸、组合药物、MOA）、适应症（阿兹海默症、帕金森氏症、血管、FTD）、给药途径、配销通路与预测，2024 年 - 2032 年
全球痴呆症与阿兹海默症相关市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测
与阿兹海默症相关的失智症市场 - 全球产业分析、规模、份额、成长、趋势和预测，2023-2031 年
全球失智症运动障碍治疗症候群市场 - 全球产业分析、规模、份额、成长、趋势、预测 (2031) - 按用于治疗的药物、按地区